Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients : a 10-year experience in a single Italian Cancer Center
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Universal screening of colorectal cancer (CRC) patients for Lynch syndrome (LS) through MisMatch Repair (MMR) testing is recommended. BRAFV600E mutation and/or MLH1 promoter methylation (Reflex Testing, RefT)generally rule out LS in MLH1-deficient (dMLH1) patients. We estimated the impact of RefTon genetic counseling (GC) and on the diagnostic yield of genetic testing (GT).
METHODS: Overall, 3199 CRC patients were referred to our center between 2011 and 2021. Patients referred until January 2019 (n=2536) underwent universal MMR testing and were termed 'Cohort A'; among patients after February 2019 (n=663), 'Cohort B', RefT was also performed in dMLH1 patients.
RESULTS: Overall, 401/3199 patients (12.5%) were MMR-deficient (dMMR); 312 (77.8%) in cohort A and 89 (22.2%) inB; 346/401 were dMLH1 (86.3%), 262/312 (83.9%) in cohort A and 84/89 (94.3%) in B. In Cohort A, 91/312 (29.1%) dMMR patients were referred to GC, 69/91 (75.8%) were in the dMLH1 group; 57/69 (82.6%) dMLH1 patients underwent GT and 1/57 (1.7%) had LS. In Cohort B, 3/84 dMLH1 patients did not undergo BRAF testing. Three BRAF wt and not hypermethylated of the remaining 81 dMLH1 patients were referred to GC and GT, and one had LS. This diagnostic pathway reduced GC referrals by 96% (78/81) in Cohort B and increased the diagnostic yield of GT by about 20 times.
CONCLUSION: Our findings support RefT in dMLH1 CRC patients within the LS diagnostic pathway, as it reduces the number of GC sessions needed and increases the diagnostic yield of GT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) - (2024) vom: 09. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Puccini, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1097/CEJ.0000000000000870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366809644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366809644 | ||
| 003 | DE-627 | ||
| 005 | 20240114233211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CEJ.0000000000000870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM366809644 | ||
| 035 | |a (NLM)38190337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Puccini, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients |b a 10-year experience in a single Italian Cancer Center |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Universal screening of colorectal cancer (CRC) patients for Lynch syndrome (LS) through MisMatch Repair (MMR) testing is recommended. BRAFV600E mutation and/or MLH1 promoter methylation (Reflex Testing, RefT)generally rule out LS in MLH1-deficient (dMLH1) patients. We estimated the impact of RefTon genetic counseling (GC) and on the diagnostic yield of genetic testing (GT) | ||
| 520 | |a METHODS: Overall, 3199 CRC patients were referred to our center between 2011 and 2021. Patients referred until January 2019 (n=2536) underwent universal MMR testing and were termed 'Cohort A'; among patients after February 2019 (n=663), 'Cohort B', RefT was also performed in dMLH1 patients | ||
| 520 | |a RESULTS: Overall, 401/3199 patients (12.5%) were MMR-deficient (dMMR); 312 (77.8%) in cohort A and 89 (22.2%) inB; 346/401 were dMLH1 (86.3%), 262/312 (83.9%) in cohort A and 84/89 (94.3%) in B. In Cohort A, 91/312 (29.1%) dMMR patients were referred to GC, 69/91 (75.8%) were in the dMLH1 group; 57/69 (82.6%) dMLH1 patients underwent GT and 1/57 (1.7%) had LS. In Cohort B, 3/84 dMLH1 patients did not undergo BRAF testing. Three BRAF wt and not hypermethylated of the remaining 81 dMLH1 patients were referred to GC and GT, and one had LS. This diagnostic pathway reduced GC referrals by 96% (78/81) in Cohort B and increased the diagnostic yield of GT by about 20 times | ||
| 520 | |a CONCLUSION: Our findings support RefT in dMLH1 CRC patients within the LS diagnostic pathway, as it reduces the number of GC sessions needed and increases the diagnostic yield of GT | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Nardin, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisan, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Lastraioli, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Gismondi, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciotti, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Damiani, Azzurra |e verfasserin |4 aut | |
| 700 | 1 | |a Bregni, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Murialdo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorino, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Martelli, Valentino |e verfasserin |4 aut | |
| 700 | 1 | |a Gandini, Annalice |e verfasserin |4 aut | |
| 700 | 1 | |a Mastracci, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Varesco, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Dono, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Battistuzzi, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Grillo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Sciallero, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) |d 1992 |g (2024) vom: 09. Jan. |w (DE-627)NLM013156993 |x 1473-5709 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CEJ.0000000000000870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 01 | ||